Alnylam Announces 2023 Product and Pipeline Goals and Provid

During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four RNAi therapeutic products, and advancement of early-, mid-, and late-stage investigational programs.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Akshay Vaishnaw , Linkedin , Twitter , Drug Administration , Alnylam Pharmaceuticals Inc , Nasdaq , Novartis , Company Rd Day , Alnylam Pharmaceuticals , Exchange Commission , Program Milestones , Securities Exchange , Pipeline Goals Detail Execution , Four Commercial Brands , Including One Potential Label Expansion , Ten Clinical Data Readouts From Proprietary , Partner Programs , Pipeline Programs , Scientific Innovation Highlighted , Organic Product Engine , Supplemental New Drug Application , Cerebral Amyloid , Investigational New Drug , Vir Biotechnology , Hepatitis Delta Virus , Partner Regeneron , Nobel Prize Winning , Securities Act , Securities Exchange Act , Quarterly Report , Alliance , Biotechnology , Diabetes , Disease , Gene Expression , Infection , Molecular Biology , Pharmaceuticals , Rna , Branches Of Biology , Inclisiran , Nucleic Acids , Rna Interference , Sanofi , Small Interfering Rna , Therapeutic Gene Modulation ,